results Good you first financial us call. for and corporate for afternoon. quarter update our joining thank And
of deadly are been know, this fight virus. coronavirus and you most the midst first the am The of pandemic. this month time of challenging a year And, on many we for to that the unusual progress sidelines we the significant against in have report productive as pleased I Capricor. not in have made
to vaccines We against develop are COVID-XX. and treatments working potential
compassionate efforts COVID-XX moments. COVID-XX, who used being will in a to discuss under our Our patients against lean product currently I is the FDA US pathway. candidates have few use CAP-XXXX treat
CAP-XXXX Dystrophy, program, our The I'm and for On on vaccine are which minutes spend update which a of progress initiatives, going the Muscular XXXX. Duchenne discussing of objectives potential exosome CAP-XXXX rapid the finally, our will COVID-XX few focus be major patients. for as this treatment our the treatment of call a for includes today, to
on was for the months level, to of MacDonald, upper you limb, released The update me HOPE-X and Yesterday it our some discuss X.XX supports let positive data multiple and to momentous P respiratory recent day approval. a Craig and first resoundingly we the the the from values was function, below call with highlights. trial. company's of clinical the data So data and Capricor, measures as XX accelerated we me with cardiac its community. Dr. hosted DMD importance believe, a
to approval presentation. the data this the bit goal for pathway on and with a later data color will DMD. in accelerating this present this presenting FDA the on highlights summer more plan HOPE-X of to We of our CAP-XXXX I
who our patients critically COVID-XX COVID-XX program, XX, we in six with Regarding treated announced CAP-XXXX. ill with results on positive April were
currently whom four of whom and discharged. are All have of been alive,
In fact, Los ABCX May television, interviewed he Tuesday, received cells saving one of the XX. in on they Angeles patients the And was life. to attribute his recently on
now Based patients with use an COVID-XX with more compassionate to the filed expanded increased. XX positive have markedly to access FDA. we data up the series, the when Cardiology Research in compared with patients May highlights in those to published on which publication peer A study, journal natural reviewed XX, survival Basic this was and the group a history titled CAP-XXXX was on IND treat We CAP-XXXX. from approval treated
elaborate more a COVID-XX add this more that XX bit However, so on also I a CAP-XXXX as later will controlled randomized submitted placebo, quickly can move a week in revised on placebo trial. to patients we well. and protocol this we into presentation
time Biological he vaccines platform Dr. end, therapeutic vaccine oncology, are vaccine strategic for conducted disease further on development, harnessing Chemistry XX, why approach COVID. pronged Professor Hopkins engineered this our as exosome our webcast for at second part plan or build Capricor's with to Johns we March a whether the explained opportunities of to that In uniquely during two of for we platforms exosome of University, infectious platform To the our capitalize Stephen are presented COVID-XX, and on a well. technology exosomes as to suited he expand and Gould,
and us Working academic with to with to the engineer Dr. access Gould develop gives a premier novel ability exosomes pipeline studies. data preclinical
throughout now, have you additional color XXXX. me we’ll this we give and let program. busy you year, various our our But to on can on a continue as build see, to for start Now, some had programs
do, commonly United what we States so Let's turn and is COVID-XX. now sickness, which and destruction coronavirus to much virus what everybody's almost the financial the This death world. causing and the economic impacting called mind everything to is and on is is
never had impact that seen the tremendous at and our lives, have the on drastically and has work. daily has have such We which way live by We taken this anything a pandemic hand. disrupted we so Capricor
we moment a two COVID-XX. ago, pronged mentioned to approach taking a I were As
to hand, one know, the late the Duchenne therapy product, storm, are illness. as later you we our Muscular On cytokine a the occurs of for stage which CAP-XXXX development treat Dystrophy a using which is clinical stage self in
other vaccine the are used hand, we a developing our On be platform to to prevent potentially exosomes COVID-XX. as
mind. that components as a the of shown have that those have CAP-XXXX is of bioactivity in thrombo COVID, main variety favoring are CAP-XXXX cytokines, papers press. released pathogenesis published of ever the stock phase as as emerging, attacks Using in causes of serendipity disease attenuate to [indiscernible] body, models well the XXX hear the inflammation viral disease which CAP-XXXX we disease and in of the been profound prepared daily which a anti-inflammatory all symptoms shock, inflammation, COVID Over case on including we CDCs a is other CDCs decided virus the popular the treat the autoimmune and We sepsis, and of in diseases. use the related exosomes because to
and person In the color. some people, the virus the without leaves recovers
terror develops cytokine the or host storm and the a in created responses. of inflammatory own trigger can do which post people inflammatory systems than good immune by situations, in virus Paradoxically, harm immune and the whole these However, stimulates there responses. the a is person our more over of a system subset
such strong data, COVID CAP-XXXX To six after of treated week a on preclinical critically ARDS million respiratory we cells, the you, protocol. ill critical series related first patients were syndrome decided Two Based using compassionate clinical acute that DMD. doses use a dose. we received with to for remind to dose two with the same in patients patients XXX distress one offer are the of and
have and remain As of today, we ICU, are patients four been from the hospital. clinically stable. the currently XXX% survival but of rate them discharged a in have Two
different Research date. Cardiology, rate those The from mentioned earlier our order a to mortality with a were week, much which we XXX% who same that patients did outcome not treated a CAP-XXXX ago, receive published peer I moments our evaluate reviewed, in those few better patient's had trajectories journal hospital, treated had along XX% in data to Center, of The six XX CAP-XXXX. the Cedars-Sinai from as the untreated patients to the Now, Medical untreated. of to were survival a the patients versus paper the treatments. group with this compared as did colleagues Basic detailing was following whether at the In a cell
patients biomarkers in with correlated publication, prior measured Additionally, and as delivery. all cell patients, poor series noted in outcomes to this of in laboratory were the
observed. such the these were related showed lymphocyte protein administration absolute infusion, CAP-XXXX important reactive from the of first in improvements Following and in was events patients ferritin, storm. No C several biomarkers to adverse as maybe counts, recovery cytokine release
expanded We to encouraged FDA access XX an were so by additional treat submitted the preliminary to up data clinical which COVID-XX been patients, for that this we has IND with approved.
begin this into to soon. patients expect enrolling We program
course and immediately portion revised XX of treat into the the placebo FDA. protocol to to to subject by critical approval trial patients patients disease. We with submitted the move controlled randomized week also is a This severe to add this placebo of
the we on surrounding hope now with which global we Based program this at are part to applying. least find concerns funding for of non-diluted COVID-XX,
program. stay very for updates on please this tuned Now important
for to not As we the hundreds continue millions, all could people. if know, thousands of of offer cells look they hope promising, if
Now to Dystrophy. turn your let attention Muscular Duchenne me
Capricor. HOPE-X data of As I momentous Based mentioned, the was and day our the for value on yesterday from trial. a strength
world We to with anxious their around the DMD. calls from are children get parents CAP-XXXX for from getting
ever placebo patients. The profound the such in treated muscle, reported DMD has perhaps multiple improve To only improvements with function, seen seen data and it. never studies the best remember, areas steroids before. impact been are cardiac other as multiple effects versus data our function, in cardiac improvement in including in was knowledge, muscle The functional steroids negatively positive such areas may of shown not of HOPE-X which have
Duchenne goal Muscular are and laser energized CAP-XXXX are We the to with focused to our bring by patients on data Dystrophy.
remind also of that treated. our all were me steroids Let patients you
drugs all cells So was of which including of standard care exosomes of the medicines, effect skipping they any for of qualified. top on the
DMD to know also the protein causes muscle and skeletal properly already of the causes dystrophin, the and degeneration muscle muscle. muscle in disorder muscle due We as lack cardiac of deterioration function fiber responsible that discipline them the a The is produces of for damage, which to lack is membrain. makes genetic unable inflammation, and which
than patients are of DMD the lose who steroid Patients Boys But non-agilent, of heart DMD to trial age DMD with young heart between longer DMD XX average boys ultimately to ages function. failure. the of to by due men of HOPE-X age. an their age XX% to years at of The them with participants are XX up have walk unfortunately XX and living of an older related leads XX. demise, depressed and and ability XX, DMD mainly with with XX% therapy, untimely these treated were
later treat no that current therapies be for yesterday. We exist. data first we very We comes cardiac the of set its to DMD. the to and line the opportunity achieving to DMD. with months of to because values, data may little the function patients multiple data very data measures said, with chance. which skeletal presented kind offer of upper P that believe advanced limb as harder final of muscle it's real data from due pleased stages XX those it The stage very top hope strong And from data the from I cardiac could were suggests the and is with the first patients was is The which HOPE-X dysfunction
there highly for that current in eligible typically occurs not boys. fibrotic the not work misgivings lot are well in patients tissue gene and therapy gene trials may a therapy the are older these Furthermore, that of the
to there the essentially I PUL Now better commonly newer, one But a X.X the discussions the the of arm. a power are test context. that to limb like called point we upper with calibrated performance would things as HOPE-X the FDA, of endpoint a recommended with is the detect registration. difference the which of the now version in in X.X efficacy Originally few PUL use that full mid-level, to primary have to the in the support they use and put
using although which the we we study. is analysis can PUL value PUL to And perform version, findings using perform full have analysis So in what the end, we a X.X clinical the of PUL. X.X most of that this the important monitor and In the P the consider this PUL, trials the see achieve. most X.XX also you full
mid-levels we very the in the X.X to data also with included. Now significance all came of close PUL
strong before improving DMD, ejection function, values cardiac never over the P of in the We very volumes trial also but global measures one and in period. year fraction seen showed
with is set data treatment clinical this outcomes together in strong very and suggest DMD. Taken CAP-XXXX
planning gave present which And you preview I compelling. I will sure very I was you the to of Now, data too. that find now, a I'm
found What of he extremely prevented steroids issues might He not that non-ambulant health responded from commonly included parameter uncommon to is one of outlier to about him non-responder. more And You several he there responding. have every that before respond was was see did had which was an the XX, presented, that age in He treated and a in the he not we we era I him might that have wanted patients have we why that every noticed but analysis understand other with is steroids. treatment. either. to the
told is it XX% a non-responder that MacDonald Dr. that us is not rate. yesterday uncommon there
in effects. strong So the fact, had and fact that not and strong the balance suggests very, data has a we a one that treatment surprising, very is
study. strong happens what highly them remove PUL data shows have can here, this endpoint effect present significant from treatment stated very to value P originally data a suggests We stand when is efficacy Shown very the FDA. merits. consider for to the and The But the mid is which what when let's to for the we value, So on which important good primary enrolled its X.X, be fully P analysis. the look an disease a orphan happens our efficacy. and own see we non-responder up X.XX, hence
we suggested significance and Again, at But PUL at look efficacy to happens out a a will what Even full look FDA the non-responder Similarly, what wouldn't when the with support we of X.XXX. of approval. with take achieved it analysis X.X. considered pull statistical of we support unequivocal value included of sign by for the The of P our at endpoint again equals requests X.XX. the approval. be P FDA in status the
opportunity respect on be the FDA data therapeutic share and goal data that to with we FDA. PUL FDA our is to and approved discussion on summer. the a that We Now, the follow X.X needs plan the this and starting exciting to process with study to welcome confirmatory convince our the this other
Now technology. on turn our last update our attention an let's not to least, but exosome
develop need Our for platform. chose medication. the as place is Obviously, global in first target, its COVID-XX our mission current and first we to exosome the using vaccines based on risks, health as the
product of primary based lot the product engineered this earlier year, his viable and in not candidate. have Dr. cell manufacturing our for University retained of Stephen Gould a exosome vaccine did announced stage of we and capabilities internal terms research early we us in to laboratory have Hopkins a Johns biologics. conduct have to We assist platform. As we development, of determining developing necessary But expertise
in to a of consultant and is way He Gould Gould's with Briefly chemistry where executive quickly. background, as case Johns collaborating biological at was you in on and the laboratory directs as this Dr. for is to while exosomes program an the Johns the especially move of develop labs Dr. he best forward vesicles. professor missed Hopkins Gould in the his the dedicated University it. Bringing University, micro Director human of understanding to of President of graduate Society program also the American Co-Founder exosome, Hopkins chemistry. disease, research context biology biological serving in and exosomes acting Dr.
we March Dr. on presentation. who will Dr. for I interesting educational hosted available The time it by are believe XX, hope Gould is I webcast. on worthwhile. was held corporate On informative, you our all the and a you Gould's find that to replay can webcast find website. to still listen
Gould vaccines the uniquely of key advantages for I the will provide you development and the with on webcast treatments. that some we exosome showed of that technology suited Dr. points our clearly that of believe and made why is it the
been First, glycoconjugates single proteins, and highly to fluids. released in approximately lipids, are cells as for nanometers about XXX acids all a while, size, and we've exosomes abundant XX selected talking enriched bio and particles. membrane They're are small in by secreted nucleic
be to concentration Normally, potential delivery over dramatically the have Exosomes excellent vehicle. distance. falls
molecule, multi-dimensional remain exosomes in a honor biochemical single pathways. from concentrations enhanced However, signaling constant, allowing signaling and
infections. limited for said, very exosomes This Vascular tissues. decisive I the as inflammation, and permeability accumulated and is tumors vascular Exosomes in includes of a an is permeability leakiness, most moment is I since of course high, wounds vascular as of which sites inflammation, sites infection ago. said advantage
strains while vaccines agents, immunization produce against recombinant are DNA most antigens recombinant pathogens live relatively attenuated comprised for Now the and virus effective often individuals protection kill immunization those attenuated DNA. against are infection, viruses, Well, and poses who both with live purified risks weak proteins, these killed many of yield other vaccine. or proteins and vaccinated coding approaches or with health
of such against newly to opportunity provides our infectious Utilizing without exosome disease as COVID-XX develop emerging risk the infection. technology vaccines
in The F E vaccine and so protein, includes collaboration its is is developing formulation lasting protein we've elicit long tripartite structural to exosome protective, immune but Dr. or much with among of the in portions This protective target is of to are a protein COVID-XX all vaccines, the our One envelope membrane the protein. primary virus. responses Gould. designed immune targeting N the also this We spine patients. of approaching mRNA or by a heard platforms SARS-CoV-X response which vaccine the M which two proteins four about,
forms that long mRNA and antigens potential Capricor that balanced induce the has to against designed for SARS-CoV-X. these expressed humeral Furthermore, response cellular are protection a and lasting
study cardiosphere-derived an The process against Capricor acid this which treat SARS-CoV-X of standard pioneered already based data free in referred on size turn exosomal to to scale extracellular are all that have very And industry produced at cell formulations, candidates called exosomes are as techniques. the these currently composition expect non-infectious studies is SARS-CoV-X. vesicle structural and nucleic virus antigen be native can other COVID-XX is virus VLP particles. the These and used by exciting is soon. [indiscernible] virus same and patients. animal by based vaccines, often cells have These free proteins range of be like to an by particles two produced We vesicles and the of
in we the XX combination proteins, offer for are there exosomes, opportunity my development, David Dr. the vaccine. potential team Goliath. could While believe and regularly, of tell novel in the four field the many years slew Gould's I the a unique that vaccines
For this exceedingly reason, our program. we are vaccine about bullish
everything technology developing are potentially in other may applied doing a vaccines platform addition, In indications. for be we
our turn to Bergmann, CFO. now our call will I over AJ
